lfg316
mAbexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01255462)
Timeline
Indications
Mechanism of action
- Complement C5INHIBITOR
C5 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- lfg316
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02878616 | Phase 1 | Aug 26, 2016 | Novartis |
| NCT02763644 | Phase 2 | Apr 22, 2016 | Novartis |
| NCT02515942 | Phase 2 | Sep 25, 2015 | Alcon, Novartis |
| NCT02534909 | Phase 2 | Sep 10, 2015 | Novartis |
| NCT01526889 | Phase 2 | Dec 20, 2012 | Novartis |
| NCT01624636 | Phase 2 | Dec 1, 2012 | Novartis |
| NCT01535950 | Phase 2 | Feb 1, 2012 | Novartis |
| NCT01527500 | Phase 2 | Jan 1, 2012 | Novartis |
| NCT01255462 | Phase 1 | Nov 1, 2010 | Novartis |
Showing 9 of 9 trials
Page 1 / 1